Abstract: Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.
Type:
Grant
Filed:
January 11, 2017
Date of Patent:
February 25, 2020
Assignee:
Merrimack Pharmaceuticals, Inc.
Inventors:
Daryl C. Drummond, Bolin Geng, Dmitri B. Kirpotin, Suresh K. Tipparaju, Alexander Koshkaryev, Ozan Alkan
Abstract: Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In oth6er aspects the biomarkers are proteins and/or nucleic acids.
Type:
Grant
Filed:
May 22, 2017
Date of Patent:
April 30, 2019
Assignee:
Merrimack Pharmaceuticals, Inc.
Inventors:
Bambang Adiwijaya, Akos Czibere, William Kubasek, Gavin MacBeath, Sharon Moulis, Rachel C. Nering, Lin Nie, Defne Yarar
Abstract: EphA2 targeted doxorubicin generating nano-liposomes are useful in the treatment of cancer overexpressing EphA2, alone or in combination with chemotherapeutic agents such as gemcitabine or carboplatin.
Abstract: Methods for predicting a therapeutic response in a patient (e.g., a cancer patient) to ErbB3 inhibitors, and methods of treating a cancer patient with targeted therapies.
Type:
Grant
Filed:
June 3, 2016
Date of Patent:
January 22, 2019
Assignee:
Merrimack Pharmaceuticals, Inc.
Inventors:
Olga Burenkova, Gavin MacBeath, Lin Nie, Mark Sevecka
Abstract: Provided are novel compositions useful for delivering nucleic acids to cells. Also provided are methods for making and using such compositions.
Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
Type:
Grant
Filed:
September 8, 2015
Date of Patent:
September 11, 2018
Assignee:
Merrimack Pharmaceuticals, Inc.
Inventors:
Raghida Bukhalid, Michael Feldhaus, Anne Richard, Neeraj Kohli, Eric Krauland, Jeffrey David Kearns, Alexey A. Lugovskoy, Ulrik Nielsen
Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
Type:
Grant
Filed:
February 24, 2014
Date of Patent:
May 29, 2018
Assignee:
Merrimack Pharmaceuticals, Inc.
Inventors:
Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
Abstract: The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.
Type:
Grant
Filed:
November 1, 2016
Date of Patent:
May 15, 2018
Assignee:
Merrimack Pharmaceuticals, Inc.
Inventors:
Daryl C. Drummond, Dmitri B. Kirpotin, Thomas Wickham, Bart S. Hendriks, Samuel Agresta, Helen Lee, Daniel F. Gaddy
Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
Type:
Grant
Filed:
August 26, 2016
Date of Patent:
April 10, 2018
Assignee:
Merrimack Pharmaceuticals, Inc.
Inventors:
Jason Baum, Bryan Johnson, Alexey Alexandrovich Lugovskoy, Lihui Xu, Neeraj Kohli, Jonathan Basil Fitzgerald, Sharlene Adams
Abstract: Methods for optimizing a therapeutic response in a patient (e.g., a cancer patient) to an anti-EGFR therapy, and methods for preventing or ameliorating infusion reactions in a patient receiving an anti-EGFR therapy are disclosed.
Abstract: Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.
Type:
Grant
Filed:
December 3, 2013
Date of Patent:
March 13, 2018
Assignee:
Merrimack Pharmaceuticals, Inc.
Inventors:
Victor Moyo, Bart S. Hendriks, Thomas Wickham, Elena Geretti, Joseph G. Reynolds, Christopher W. Espelin
Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
Type:
Grant
Filed:
September 8, 2015
Date of Patent:
February 27, 2018
Assignee:
Merrimack Pharmaceuticals, Inc.
Inventors:
Raghida Bukhalid, Michael Feldhaus, Anne Richard, Neeraj Kohli, Eric Krauland, Jeffrey David Kearns, Alexey A. Lugovskoy, Ulrik Nielsen
Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
Type:
Grant
Filed:
September 8, 2015
Date of Patent:
February 6, 2018
Assignee:
Merrimack Pharmaceuticals, Inc.
Inventors:
Raghida Bukhalid, Michael Feldhaus, Anne Richard, Neeraj Kohli, Eric Krauland, Jeffrey David Kearns, Alexey A. Lugovskoy, Ulrik Nielsen
Abstract: Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In other aspects the biomarkers are proteins and/or nucleic acids.
Type:
Application
Filed:
May 22, 2017
Publication date:
September 21, 2017
Applicants:
Merrimack Pharmaceuticals, Inc., Merrimack Pharmaceuticals, Inc.
Inventors:
Bambang ADIWIJAYA, Akos CZIBERE, William KUBASEK, Gavin MACBEATH, Sharon MOULIS, Rachel C. NERING, Lin NIE, Defne YARAR
Abstract: Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-HER2 antibody that is not an inhibitor of HER2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-HER2 antibody.
Type:
Application
Filed:
May 18, 2017
Publication date:
September 14, 2017
Applicant:
Merrimack Pharmaceuticals, Inc.
Inventors:
Christopher W. Espelin, Elena Geretti, Bart S. Hendriks, Victor Moyo, Joseph G. Reynolds, Thomas Wickham
Abstract: Disclosed herein are methods of treating pancreatic cancer in a human patient by co-administering istiratumab in combination with gemcitabine and nab-paclitaxel, and dosage regimens for the same.
Type:
Application
Filed:
January 19, 2017
Publication date:
August 17, 2017
Applicant:
Merrimack Pharmaceuticals, Inc.
Inventors:
Alexey Alexandrovich LUGOVSKOY, Jason BAUM, Chrystal U. LOUIS
Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
Type:
Grant
Filed:
December 14, 2015
Date of Patent:
August 1, 2017
Assignee:
Merrimack Pharmaceuticals, Inc.
Inventors:
Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
Type:
Application
Filed:
January 18, 2017
Publication date:
July 6, 2017
Applicant:
Merrimack Pharmaceuticals, Inc.
Inventors:
Joseph G. Reynolds, Kenneth J. Olivier, JR., Bart S. Hendriks, Thomas Wickham, Stephan Klinz, Elena Geretti
Abstract: Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In other aspects the biomarkers are proteins and/or nucleic acids.
Type:
Grant
Filed:
December 10, 2015
Date of Patent:
June 27, 2017
Assignee:
Merrimack Pharmaceuticals, Inc.
Inventors:
Bambang Adiwijaya, Akos Czibere, William Kubasek, Gavin MacBeath, Sharon Moulis, Rachel C. Nering, Lin Nie, Defne Yarar
Abstract: Methods for optimizing a therapeutic response in a patient (e.g., a cancer patient) to an anti-EGFR therapy, and methods for preventing or ameliorating infusion reactions in a patient receiving an anti-EGFR therapy are disclosed.